Summary
BIND Therapeutics Inc (BIND Therapeutics) is a nanomedicine platform company that develops and commercializes preclinical candidates for cardiovascular disease, cancer and inflammatory disease. The company’s pipeline products include BIND-014, an Accurin that contains the well-established chemotherapeutic agent, docetaxel. It provides AZD-2811, targeted kinase inhibitor, bind-267, and bind-787. BIND Therapeutics also develops oligonucleotides, immuno-oncology, tam targeting, and GC-C. BIND Therapeutic's medicinal nanoengineering platform overcomes this limitation by adding unprecedented ability to enhance the trafficking of drugs to tumors, while minimizing exposure of healthy tissues. The company operates through its office located in Russia. BIND Therapeutics is headquartered in Cambridge, Massachusetts, the US.
BIND Therapeutics Inc (BIND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BIND Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
BIND Therapeutics Secures USD15 Million from Hercules Technology 11
Bind Biosciences Raises US$8.7 Million In Venture Financing 11
Bind Biosciences Secures US$35 Million In Series D Financing Round 12
BIND Biosciences Secures US$4.7 Million In Venture Financing 14
Partnerships 15
BIND Therapeutics Forms Partnership with Affilogic 15
PeptiDream Enters into Research Agreement with BIND Therapeutics 16
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 16
BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 17
BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 18
Bind Therapeutics Enters into R&D Agreement with Merck 19
Bind Therapeutics Enters into Research Agreement with Roche for Accurins 20
Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 20
Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 22
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 23
Licensing Agreements 24
Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 24
Equity Offering 25
BIND Therapeutics Raises USD21 Million in Public Offering of Shares and Warrants 25
Bind Therapeutics Completes IPO For US$70.5 Million 26
Asset Transactions 27
Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 27
BIND Therapeutics Inc - Key Competitors 30
Key Employees 31
Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33
List of Tables
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BIND Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BIND Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
BIND Therapeutics Secures USD15 Million from Hercules Technology 11
Bind Biosciences Raises US$8.7 Million In Venture Financing 11
Bind Biosciences Secures US$35 Million In Series D Financing Round 12
BIND Biosciences Secures US$4.7 Million In Venture Financing 14
BIND Therapeutics Forms Partnership with Affilogic 15
PeptiDream Enters into Research Agreement with BIND Therapeutics 16
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 16
BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 17
BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 18
Bind Therapeutics Enters into R&D Agreement with Merck 19
Bind Therapeutics Enters into Research Agreement with Roche for Accurins 20
Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 20
Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 22
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 23
Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 24
BIND Therapeutics Raises USD21 Million in Public Offering of Shares and Warrants 25
Bind Therapeutics Completes IPO For US$70.5 Million 26
Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 27
BIND Therapeutics Inc, Key Competitors 30
BIND Therapeutics Inc, Key Employees 31
List of Figures
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
